326 related articles for article (PubMed ID: 18602960)
1. A double-blind, placebo-controlled trial to evaluate the efficacy of PTL-003, an attenuated enterotoxigenic E. coli (ETEC) vaccine strain, in protecting against challenge with virulent ETEC.
McKenzie R; Darsley M; Thomas N; Randall R; Carpenter C; Forbes E; Finucane M; Sack RB; Hall E; Bourgeois AL
Vaccine; 2008 Aug; 26(36):4731-9. PubMed ID: 18602960
[TBL] [Abstract][Full Text] [Related]
2. Comparative safety and immunogenicity of two attenuated enterotoxigenic Escherichia coli vaccine strains in healthy adults.
McKenzie R; Bourgeois AL; Engstrom F; Hall E; Chang HS; Gomes JG; Kyle JL; Cassels F; Turner AK; Randall R; Darsley M; Lee C; Bedford P; Shimko J; Sack DA
Infect Immun; 2006 Feb; 74(2):994-1000. PubMed ID: 16428745
[TBL] [Abstract][Full Text] [Related]
3. Construction and phase I clinical evaluation of the safety and immunogenicity of a candidate enterotoxigenic Escherichia coli vaccine strain expressing colonization factor antigen CFA/I.
Turner AK; Beavis JC; Stephens JC; Greenwood J; Gewert C; Thomas N; Deary A; Casula G; Daley A; Kelly P; Randall R; Darsley MJ
Infect Immun; 2006 Feb; 74(2):1062-71. PubMed ID: 16428753
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and protective efficacy of a single-dose live non-pathogenic Escherichia coli oral vaccine against F4-positive enterotoxigenic Escherichia coli challenge in pigs.
Fairbrother JM; Nadeau É; Bélanger L; Tremblay CL; Tremblay D; Brunelle M; Wolf R; Hellmann K; Hidalgo Á
Vaccine; 2017 Jan; 35(2):353-360. PubMed ID: 27916413
[TBL] [Abstract][Full Text] [Related]
5. Vaccines against enterotoxigenic Escherichia coli.
Svennerholm AM; Tobias J
Expert Rev Vaccines; 2008 Aug; 7(6):795-804. PubMed ID: 18665777
[TBL] [Abstract][Full Text] [Related]
6. Live attenuated enterotoxigenic Escherichia coli (ETEC) vaccine with dmLT adjuvant protects human volunteers against virulent experimental ETEC challenge.
Harro C; Louis Bourgeois A; Sack D; Walker R; DeNearing B; Brubaker J; Maier N; Fix A; Dally L; Chakraborty S; Clements JD; Saunders I; Darsley MJ
Vaccine; 2019 Mar; 37(14):1978-1986. PubMed ID: 30797634
[TBL] [Abstract][Full Text] [Related]
7. Prime-boost vaccine regimen confers protective immunity to human-derived enterotoxigenic Escherichia coli.
Lasaro MO; Luiz WB; Sbrogio-Almeida ME; Ferreira LC
Vaccine; 2005 Mar; 23(19):2430-8. PubMed ID: 15752829
[TBL] [Abstract][Full Text] [Related]
8. Oral immunization of a live attenuated Escherichia coli strain expressing a holotoxin-structured adhesin-toxoid fusion (1FaeG-FedF-LTA₂:5LTB) protected young pigs against enterotoxigenic E. coli (ETEC) infection.
Ruan X; Zhang W
Vaccine; 2013 Mar; 31(11):1458-63. PubMed ID: 23375979
[TBL] [Abstract][Full Text] [Related]
9. Comparative evaluation of a vaccine candidate expressing enterotoxigenic Escherichia coli (ETEC) adhesins for colibacillosis with a commercial vaccine using a pig model.
Hur J; Lee JH
Vaccine; 2012 Jun; 30(26):3829-33. PubMed ID: 22507658
[TBL] [Abstract][Full Text] [Related]
10. Lactobacillus acidophilus supplementation in human subjects and their resistance to enterotoxigenic Escherichia coli infection.
Ouwehand AC; ten Bruggencate SJ; Schonewille AJ; Alhoniemi E; Forssten SD; Bovee-Oudenhoven IM
Br J Nutr; 2014 Feb; 111(3):465-73. PubMed ID: 23930950
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized, placebo-controlled Phase I study.
Lundgren A; Bourgeois L; Carlin N; Clements J; Gustafsson B; Hartford M; Holmgren J; Petzold M; Walker R; Svennerholm AM
Vaccine; 2014 Dec; 32(52):7077-84. PubMed ID: 25444830
[TBL] [Abstract][Full Text] [Related]
12. Analysis of efficacy of CVD 103-HgR live oral cholera vaccine against all-cause travellers' diarrhoea in a randomised, double-blind, placebo-controlled study.
Leyten EM; Soonawala D; Schultsz C; Herzog C; Ligthelm RJ; Wijnands S; Visser LG
Vaccine; 2005 Oct; 23(43):5120-6. PubMed ID: 15982790
[TBL] [Abstract][Full Text] [Related]
13. Recent progress toward an enterotoxigenic Escherichia coli vaccine.
Svennerholm AM; Lundgren A
Expert Rev Vaccines; 2012 Apr; 11(4):495-507. PubMed ID: 22551034
[TBL] [Abstract][Full Text] [Related]
14. The oral, live attenuated enterotoxigenic Escherichia coli vaccine ACE527 reduces the incidence and severity of diarrhea in a human challenge model of diarrheal disease.
Darsley MJ; Chakraborty S; DeNearing B; Sack DA; Feller A; Buchwaldt C; Bourgeois AL; Walker R; Harro CD
Clin Vaccine Immunol; 2012 Dec; 19(12):1921-31. PubMed ID: 23035175
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of a single oral dose of a live bivalent E. coli vaccine against post-weaning diarrhea due to F4 and F18-positive enterotoxigenic E. coli.
Nadeau É; Fairbrother JM; Zentek J; Bélanger L; Tremblay D; Tremblay CL; Röhe I; Vahjen W; Brunelle M; Hellmann K; Cvejić D; Brunner B; Schneider C; Bauer K; Wolf R; Hidalgo Á
Vet J; 2017 Aug; 226():32-39. PubMed ID: 28911838
[TBL] [Abstract][Full Text] [Related]
16. Strategies to overexpress enterotoxigenic Escherichia coli (ETEC) colonization factors for the construction of oral whole-cell inactivated ETEC vaccine candidates.
Tobias J; Svennerholm AM
Appl Microbiol Biotechnol; 2012 Mar; 93(6):2291-300. PubMed ID: 22350259
[TBL] [Abstract][Full Text] [Related]
17. Characterization of Mucosal Immune Responses to Enterotoxigenic Escherichia coli Vaccine Antigens in a Human Challenge Model: Response Profiles after Primary Infection and Homologous Rechallenge with Strain H10407.
Chakraborty S; Harro C; DeNearing B; Ram M; Feller A; Cage A; Bauers N; Bourgeois AL; Walker R; Sack DA
Clin Vaccine Immunol; 2016 Jan; 23(1):55-64. PubMed ID: 26581889
[TBL] [Abstract][Full Text] [Related]
18. Administration of purified colonization factor antigens (CFA/I, CFA/II) of enterotoxigenic Escherichia coli to volunteers. Response to challenge with virulent enterotoxigenic Escherichia coli.
Evans DG; Graham DY; Evans DJ
Gastroenterology; 1984 Oct; 87(4):934-40. PubMed ID: 6381216
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability, and immunogenicity of an oral inactivated ETEC vaccine (ETVAX®) with dmLT adjuvant in healthy adults and children in Zambia: An age descending randomised, placebo-controlled trial.
Sukwa N; Mubanga C; Hatyoka LM; Chilyabanyama ON; Chibuye M; Mundia S; Munyinda M; Kamuti E; Siyambango M; Badiozzaman S; Bosomprah S; Carlin N; Kaim J; Sjöstrand B; Simuyandi M; Chilengi R; Svennerholm AM
Vaccine; 2023 Nov; 41(46):6884-6894. PubMed ID: 37838479
[TBL] [Abstract][Full Text] [Related]
20. Reduced doses of oral killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine is safe and immunogenic in Bangladeshi infants 6-17 months of age: dosing studies in different age groups.
Qadri F; Ahmed T; Ahmed F; Begum YA; Sack DA; Svennerholm AM;
Vaccine; 2006 Mar; 24(10):1726-33. PubMed ID: 16257098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
